Abstract
Due to the COVID-19 pandemic, there is a high demand for Susceptible-Infective-Recovered (SIR) models to adjust and predict the number of cases in urban areas. Forecasting, however, is a difficult task, because the change in people’s behavior reflects in a continuous change in the parameters of the model. An important question is what we can use from one city to another; if what happened in Madrid could have been applied to New York and then, if what we have learned from this city would be useful for São Paulo. To answer this question, we present an analysis of the transmission rate of COVID-19 as a function of population density and population size for US counties, cities of Brazil, German, and Portugal. Contrary to the common hypothesis in epidemics modeling, we observe a higher disease transmissibility for higher city’s population density/size –with the latter showing more predicting power. We present a contact rate scaling theory that explain the results, predicting that the basic reproductive number R0 of epidemics scales as the logarithm of the city size.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SG acknowledges CAPES for support, under fellowship #003/2019 - PROPG - PRINT/UFRGS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present research was conducted using COVID-19 and demographic data solely from public sites. No human was involved in this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available from authors under request
